

# Clinical Trial Protocol

## Iranian Registry of Clinical Trials

01 Jul 2026

### Comparative study of the effect of concomitant use of Lactobacillus Ramnosus probiotic and oral antifungal nystatin on inhibitory intestinal colony growth in Candida albicans in infants under 2500 g

#### Protocol summary

##### Study aim

Comparative study of the effect of concomitant use of Lactobacillus Ramnosus probiotic and oral antifungal nystatin on inhibitory intestinal colony growth in Candida albicans in infants under 2500 g

##### Design

This study is a double-blind clinical trial with a parallel design and a control group. The study population will include all infants weighing less than 2500 grams hospitalized in Mohammad Kermanshahi Hospital. 100 eligible babies will be selected conveniently. For randomization, permutation block is used and participants are assigned to intervention and control groups.

##### Settings and conduct

This study, which will be performed in Mohammad Kermanshahi Hospital, is a double-blinded one. Participants and statistical analysts are unaware of the allocation of the intervention and control group. Samples are processed in the laboratory within two hours and cultured in a general medium such as sabrodextrose agar. Two candida culture samples are taken from each infant from the stool (the first sample at 1 to 3 days of age and before the start of medication, and the second sample 7 days later).

##### Participants/Inclusion and exclusion criteria

Inclusion criteria: Birth weight 2500 grams and less; Age of hospitalization time 72 hours and less Exclusion criteria: Maternal use of oral and topical antifungals during the last month of pregnancy

##### Intervention groups

The intervention group will receive 10 drops of nystatin 100,000 oral units 3 times a day along with 10 oral drops of Ramnoflor (Lactobacillus Ramnosus) in the mouth once a day (4 times in total). The control group will receive 10 drops of placebo (distilled water) 4 times a day.

#### Main outcome variables

Duration of hospitalization; Necrotizing enterocolitis

#### General information

##### Reason for update

##### Acronym

##### IRCT registration information

IRCT registration number: **IRCT20130812014333N175**

Registration date: **2021-09-25, 1400/07/03**

Registration timing: **prospective**

Last update: **2021-09-25, 1400/07/03**

Update count: **0**

##### Registration date

2021-09-25, 1400/07/03

##### Registrant information

##### Name

Feizollah Foroughi

##### Name of organization / entity

kermanshah University of Medical Sciences

##### Country

Iran (Islamic Republic of)

##### Phone

+98 83 1821 4653

##### Email address

fforoughi@kums.ac.ir

##### Recruitment status

**Recruitment complete**

##### Funding source

##### Expected recruitment start date

2021-10-02, 1400/07/10

##### Expected recruitment end date

2022-01-30, 1400/11/10

##### Actual recruitment start date

empty

**Actual recruitment end date**

empty

**Trial completion date**

empty

**Scientific title**

Comparative study of the effect of concomitant use of Lactobacillus Ramnosus probiotic and oral antifungal nystatin on inhibitory intestinal colony growth in Candida albicans in infants under 2500 g

**Public title**

the effect of concomitant use of Lactobacillus Ramnosus probiotic and oral antifungal nystatin on inhibitory intestinal colony growth in Candida albicans in infants under 2500 g

**Purpose**

Treatment

**Inclusion/Exclusion criteria****Inclusion criteria:**

Birth weight 2500 grams and less Age of hospitalization time 72 hours and less

**Exclusion criteria:**

Maternal use of oral and topical antifungals during the last month of pregnancy

**Age**

From **1 day** old to **3 days** old

**Gender**

Both

**Phase**

2-3

**Groups that have been masked**

- Participant
- Data analyser

**Sample size**

Target sample size: **100**

**Randomization (investigator's opinion)**

Randomized

**Randomization description**

For random allocation, permuted block randomization method is used to balance the number of samples assigned to each of the study groups. This method is done by selecting blocks with the size of each quadruple block (2 participants in the intervention group and 2 participants in the control group) and each of the 6 possible cases of numbers for the quad block is assigned as follows: 1) AABB 2) ABAB 3) ABBA 4) BBAA 5) BABA 6) BAAB. Using a table of random numbers, the numbers between 1 and 6 are selected and in accordance with each number, the allocation list of the intervention or control group will be determined, thus sampling will continue until the end of the samples.

**Blinding (investigator's opinion)**

Double blinded

**Blinding description**

In this study, participants and statistical analysts are unaware of the nature of control or intervention of groups A and B. Medications can only be identified by the serial number on the container. The serials are with the main researcher and will remain confidential until the end of the study

**Placebo**

Used

**Assignment**

Parallel

**Other design features****Secondary Ids**

empty

**Ethics committees****1****Ethics committee****Name of ethics committee**

Ethics committee of Kermanshah University of Medical Sciences

**Street address**

Vice Chancellor for Research Affairs, Kermanshah University of Medical Sciences, Building No.2, Shahid Beheshti Boulevard

**City**

Kermanshah

**Province**

Kermanshah

**Postal code**

6715847141

**Approval date**

2021-08-31, 1400/06/09

**Ethics committee reference number**

IR.KUMS.REC.1400.426

**Health conditions studied****1****Description of health condition studied**

candida colonization

**ICD-10 code**

P37.5

**ICD-10 code description**

Neonatal candidiasis

**Primary outcomes****1****Description**

Duration of hospitalization

**Timepoint**

End of study (10 days after starting the study)

**Method of measurement**

According to documents

**2****Description**

Necrotizing enterocolitis

**Timepoint**

End of study (10 days after starting the study)

**Method of measurement**

Based on the doctor's diagnosis

## Secondary outcomes

empty

## Intervention groups

1

### Description

The intervention group will receive 10 drops of nystatin 100,000 oral units 3 times a day along with 10 oral drops of Ramnoflor (Lactobacillus Ramnosus) in the mouth once a day (4 times in total).

### Category

Treatment - Drugs

2

### Description

The control group will receive 10 drops of placebo (distilled water) 4 times a day.

### Category

Treatment - Other

## Recruitment centers

1

### Recruitment center

#### Name of recruitment center

Mohammad Kermanshahi Hospital

#### Full name of responsible person

Farzad Mashreghi

#### Street address

Mohammad Kermanshahi Hospital, Helal Ahmar  
Crossroad

#### City

Kermanshah

#### Province

Kermanshah

#### Postal code

6713733135

#### Phone

+98 83 3721 8202

#### Email

farzadmashreghi@gmail.com

## Sponsors / Funding sources

1

### Sponsor

#### Name of organization / entity

Kermanshah University of Medical Sciences

#### Full name of responsible person

Dr. Reza Khodarahmi

#### Street address

Vice Chancellor for Research Affairs, Kermanshah  
University of Medical Sciences, Building No.2, Shahid  
Beheshti Boulevard

### City

Kermanshah

### Province

Kermanshah

### Postal code

6715847141

### Phone

+98 83 3836 0014

### Email

rkhodarahmi@kums.ac.ir

### Grant name

### Grant code / Reference number

### Is the source of funding the same sponsor organization/entity?

Yes

### Title of funding source

Kermanshah University of Medical Sciences

### Proportion provided by this source

100

### Public or private sector

Public

### Domestic or foreign origin

Domestic

### Category of foreign source of funding

empty

### Country of origin

### Type of organization providing the funding

Academic

## Person responsible for general inquiries

### Contact

#### Name of organization / entity

Kermanshah University of Medical Sciences

#### Full name of responsible person

Farzad Mashreghi

#### Position

Resident of Children

#### Latest degree

Medical doctor

#### Other areas of specialty/work

Pediatrics

#### Street address

Mohammad Kermanshahi Hospital, Helal Ahmar  
Crossroad

#### City

Kermanshah

#### Province

Kermanshah

#### Postal code

6713733135

#### Phone

+98 83 3721 8202

#### Email

farzadmashreghi@gmail.com

## Person responsible for scientific inquiries

### Contact

#### Name of organization / entity

Kermanshah University of Medical Sciences

**Full name of responsible person**

Dr. Maziar Vakili Amini

**Position**

Faculty member of Kermanshah University of Medical Sciences

**Latest degree**

Subspecialist

**Other areas of specialty/work**

Pediatrics

**Street address**

Mohammad Kermanshahi Hospital, Helal Ahmar Crossroad

**City**

Kermanshah

**Province**

Kermanshah

**Postal code**

6713733135

**Phone**

+98 83 3721 8205

**Email**

mzvakilia@ac.ir .com

**Other areas of specialty/work**

Pediatrics

**Street address**

Mohammad Kermanshahi Hospital, Helal Ahmar Crossroad

**City**

Kermanshah

**Province**

Kermanshah

**Postal code**

6713733135

**Phone**

+98 83 3721 8202

**Email**

farzadmashreghi@gmail.com

**Person responsible for updating data****Contact****Name of organization / entity**

Kermanshah University of Medical Sciences

**Full name of responsible person**

Farzad Mashreghi

**Position**

Resident of Children

**Latest degree**

Medical doctor

**Sharing plan****Deidentified Individual Participant Data Set (IPD)**

No - There is not a plan to make this available

**Justification/reason for indecision/not sharing IPD**

There is no more information

**Study Protocol**

No - There is not a plan to make this available

**Statistical Analysis Plan**

No - There is not a plan to make this available

**Informed Consent Form**

No - There is not a plan to make this available

**Clinical Study Report**

No - There is not a plan to make this available

**Analytic Code**

No - There is not a plan to make this available

**Data Dictionary**

No - There is not a plan to make this available